Shire Pharma Canada ULC, a subsidiary of Takeda Pharmaceutical Company, is a leading player in the biopharmaceutical industry, headquartered in Canada. Established in 1986, Shire has made significant strides in developing innovative therapies for rare diseases, particularly in the fields of neuroscience, immunology, and genetic disorders. With a strong presence across Canada, Shire is renowned for its core products, including treatments for attention deficit hyperactivity disorder (ADHD) and rare genetic conditions. The company’s commitment to patient-centric solutions and its robust pipeline of unique therapies have solidified its position as a trusted name in the pharmaceutical landscape. Notable achievements include pioneering advancements in enzyme replacement therapies, which have transformed the lives of patients with rare metabolic disorders.
We don't have data for Shire Pharma Canada ULC, but we can show you information about their parent organization instead.
View parent company